Mauna Kea Technologies Stock price

Equities

ALMKT

FR0010609263

Advanced Medical Equipment & Technology

Real-time Euronext Paris 12:35:13 2024-03-28 pm EDT 5-day change 1st Jan Change
0.428 EUR +3.01% Intraday chart for Mauna Kea Technologies +12.04% -9.13%
Sales 2023 * 8.4M 9.05M Sales 2024 * 9.6M 10.35M Capitalization 26.34M 28.39M
Net income 2023 * -5M -5.39M Net income 2024 * -6M -6.47M EV / Sales 2023 * 6.96 x
Net Debt 2023 * 32.1M 34.59M Net Debt 2024 * 38.7M 41.71M EV / Sales 2024 * 6.78 x
P/E ratio 2023 *
-3.57 x
P/E ratio 2024 *
-2.85 x
Employees 67
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.84%
More Fundamentals * Assessed data
Dynamic Chart
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio CI
Mauna Kea: partnership with Metrodora Institute in the USA CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults CI
Mauna Kea: Johnson & Johnson Innovation below 20% threshold CF
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals MT
Mauna Kea: share price surges as Telix acquires 19% stake CF
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery CI
Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited CI
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer CI
Mauna Kea Technologies Reports Sales Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone CI
Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris MT
Transcript : Mauna Kea Technologies SA, H1 2023 Sales/ Trading Statement Call, Jul 20, 2023
Mauna Kea Technologies Announces the Installation of Cellvizio at University College Cork - APC Microbiome Ireland for Inflammatory Bowel Disease Applications CI
More news
1 day+3.01%
1 week+12.04%
Current month-1.38%
1 month-2.28%
3 months-9.13%
6 months-25.82%
Current year-9.13%
More quotes
1 week
0.34
Extreme 0.3415
0.46
1 month
0.34
Extreme 0.3415
0.46
Current year
0.34
Extreme 0.3415
0.52
1 year
0.34
Extreme 0.3415
0.77
3 years
0.34
Extreme 0.3415
1.81
5 years
0.34
Extreme 0.3415
2.37
10 years
0.34
Extreme 0.3415
13.27
More quotes
Managers TitleAgeSince
Chief Executive Officer - 00-04-30
Director of Finance/CFO - 23-06-12
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member - 07-12-31
Chief Executive Officer - 00-04-30
Director/Board Member 60 18-01-14
More insiders
Date Price Change Volume
24-03-28 0.428 +3.01% 534,790
24-03-27 0.4155 +15.10% 289,901
24-03-26 0.361 -1.77% 198,821
24-03-25 0.3675 -0.81% 85,332
24-03-22 0.3705 -3.01% 116,109

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools. The group's products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. Net sales break down by activity as follows: - sales of accessories (41.9%): mini-probes, software, etc.; - sales of system (39.8%); - services (18.3%). Net sales are distributed geographically as follows: the United States and Canada (56.2%), Asia/Pacific (5.4%), Europe-Middle East-Africa and other (38.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.428 EUR
Average target price
1.955 EUR
Spread / Average Target
+356.78%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Mauna Kea Technologies - Euronext Paris